Ipsen Buys Botulinum Toxin Specialist Syntaxin for $206M

LONDON  The UK botulinum toxin specialist Syntaxin Ltd. is to be acquired by research partner and equity investor Ipsen SA in a deal that potentially is worth €158 million (US$205.8 million), with €28 million to be paid up front, and the remainder tied to development and commercialization milestones.